Live Tissue Science™
A Patient Driven Approach
Live Tissue Science™ moves beyond routine therapies, creating access to researchers, clinical trials, ex vivo therapy testing, clinical vaccines, organoid creation and more.
Every Tumor Is Unique and Individual Precision Medicine Brings New Hope
How the Medical Community Advances
The global medical community knows it cannot treat cancer as if “one size fits all,” recognizing more than 9.5 million people will die this year, 14 times the number of deaths to date from the global pandemic. Functional precision medicine with a focus on Live Tissue Science™ is how we break the wheel of cancer deaths.
*Source: International Agency for Research on Cancer (IARC).
From 10% to 50%
Genomic Medicine was a breakthrough 10 years ago, and it remains relevant today as the first stage of our work. But, cancer treatment was falling behind until “live tissue science.” We can advance treatment from 10% (genomic) to as high as 50% (live tissue science) success rates.
Options with Live Tissue Science
TUMOR-INFILTRATING LYMPHOCYTE (TILS)
Cancer is a genetic disease that is caused by changes in the DNA that change the way cells function. By testing your unique combination of genetic changes and tumor DNA sequencing, researchers can help provide information to your medical team that can aid in their treatment planning. Knowledge of your specific genetic mutation profile helps especially in identifying targeted therapies and finding precise options showing the most promise for your genetic make-up.
ACCESS TO CLINICAL TRIALS
Your tumor tissue can be used to create a vaccine that is personal to your cancer, body and immune system. The vaccine will allow your body to recognize the cancer cells so it can more effectively fight them while stimulating your immune system.
Empowers the Patient
“Our Individual Precision Medicine process developed with SpeciCare takes living tissue from the patient to preserve in several formats, thereby maximizing opportunities for its use for the patient’s benefit. This biological material is preserved using advanced cryopreservation methods that are consistent with industry-leading biorepositories and in vitro fertilization clinics worldwide. All tissue is reviewed by ASCP-certified Cytotechnologists and Pathologists to document its content and quality.We are pleased with this medical advancement because it empowers the patient to take part in their own outcomes. By preserving cells and tissue from the patient and giving them ownership, they become an active participant in the treatment process. Together with SpeciCare, we believe by increasing the availability of high-quality specimens, cancer treatment can evolve to a more informed and targeted process at the individual level.”
Dr. Carol C. Eisenhut MD, MBA, President, DCL Pathology, SpeciCare Partner